6.2 Stability, Shelf-Life, and Manufacturing

Reaction Kinetics in Drug Stability

Drug degradation is modeled with the same rate laws used in general chemistry. Knowing the order tells the formulator how concentration affects shelf-life and how to extrapolate accelerated data.

• Zero-order: rate is constant, independent of drug concentration. dC/dt = −k0. Example: suspension suspensions where the surface area of excess solid maintains a saturated solution. Half-life depends on initial concentration: t1/2 = C0 / (2k0).
• First-order: rate proportional to concentration. dC/dt = −k1·C. Most drug degradations follow first-order kinetics. Half-life t1/2 = 0.693/k1 is independent of C0.
• Second-order: rate proportional to product of two concentrations (or squared). dC/dt = −k2·C². Common when two drug molecules react together.
• Pseudo-order: a reactant is in vast excess so its concentration is effectively constant, and a higher-order reaction collapses to a lower apparent order (e.g., hydrolysis in water is pseudo-first-order because water concentration is ~55.5 M).

Shelf-Life Determination and Accelerated Stability

Pharmaceutical shelf-life (expiration date) is the time the product remains within specification when stored under labeled conditions. The conventional potency cutoff is 90% of labeled claim, defining t90. For first-order decay, t90 = ln(0.90)/(−k) ≈ 0.105/k.

Accelerated stability testing uses elevated temperature to provoke degradation quickly, then extrapolates to refrigerator or room-temperature conditions using the Arrhenius equation:

k = A · exp(−Ea / (R · T))

where k is the rate constant, A the pre-exponential factor, Ea the activation energy, R the gas constant (8.314 J·mol⁻¹·K⁻¹), and T the absolute temperature. Plotting ln k versus 1/T (Kelvin) yields a straight line whose slope equals −Ea/R. Once Ea is known, the formulator calculates k at 25 °C and the corresponding t90.

ICH guidance recommends: long-term (25 °C/60% RH, 12 months), intermediate (30 °C/65% RH, 6 months), and accelerated (40 °C/75% RH, 6 months) conditions. A product that remains within specification at accelerated conditions for six months generally supports a tentative 24-month shelf-life at room temperature, confirmed by long-term data.

Physical and Chemical Stability

Physical instability changes appearance or performance without breaking covalent bonds: polymorphic conversion (anhydrous ↔ hydrate), hygroscopic uptake of water, crystal growth in suspensions, phase separation in emulsions, caking, color change, odor development. Polymorphic transitions can collapse solubility — the metastable form of ritonavir (Form II) precipitated from capsules in 1998, forcing a market withdrawal.

Chemical instability breaks the drug molecule:

• Hydrolysis — esters, amides, lactams, lactones cleave in water; catalyzed by acid, base, or specific pH. Aspirin hydrolyzes to salicylic acid and acetic acid; penicillins and cephalosporins hydrolyze at the beta-lactam ring.
• Oxidation — electron loss, often initiated by light, trace metals, or oxygen. Examples: vitamin A, ascorbic acid, epinephrine, morphine (turns brown), nitroprusside. Stabilize with antioxidants (BHA, BHT, ascorbic acid, sodium metabisulfite), chelating agents (EDTA binds Fe²⁺/Cu²⁺ that catalyze Fenton chemistry), nitrogen flushing, and amber containers that block UV.
• Photolysis — UV-visible absorption excites the molecule; nifedipine, riboflavin, nitrofurazone are notoriously photolabile. Use amber or opaque packaging and store protected from light.

Drug Product Manufacturing under cGMP

Current Good Manufacturing Practice (cGMP) is the FDA regulatory framework (21 CFR 210/211) that assures identity, strength, quality, purity, and potency. Validation, batch records, deviation management, change control, and stability commitment are continuous obligations, not one-time checks.

Tablet manufacturing routes:

• Wet granulation — binder solution aggregates powder into granules of uniform size; dries, mills, blends with lubricant, compresses. Ideal for low-dose drugs (improves content uniformity) and poor-flow powders.
• Dry granulation — roller compaction or slugging forms granules without water; suited for water-sensitive drugs.
• Direct compression — compresses pre-blended API and excipients; fewest steps, but requires good-flow excipients (microcrystalline cellulose, spray-dried lactose).

Coating — sugar, film, or enteric polymer applied in pan or fluidized-bed coaters. Film coats protect the drug, mask taste, and improve appearance; enteric coats resist gastric acid and dissolve in the intestine (pH ~6.8).

Quality Control Tests

• Content uniformity — assures each unit contains 85-115% of label claim with low variability (USP <905>).
• Dissolution testing — USP Apparatus 1/2 with Q-point specifications (e.g., Q=80% in 45 min).
• Hardness (crushing strength) — affects disintegration and handling; typically 4-10 kg for tablets.
• Friability — weight loss after drum rotation (USP <1216>); must be <1%.
• Disintegration — bounded time limits in specified media (USP <701>).
• Assay and impurities — HPLC/UPLC quantitation of API and degradation products against ICH Q3B thresholds.

Formulation-Biological Interactions

Excipients and food can change absorption. Food effects: a high-fat meal can slow gastric emptying and alter dissolution for poorly soluble drugs, sometimes doubling exposure (grapefruit juice inhibits intestinal CYP3A4, raising statin levels). Excipient interactions: calcium and magnesium antacids chelate fluoroquinolones and tetracyclines, sharply reducing bioavailability. Lactose in large doses can raise blood glucose; sorbitol can cause diarrhea. Such interactions explain why bioequivalence studies use fasting and fed arms.